Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News DermTech Inc DMTKQ

Healthcare Biotechnology
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma... see more

Recent & Breaking News (OTCPK:DMTKQ)

The Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

Business Wire September 15, 2023

DermTech Appoints Mark Aguillard as Chief Commercial Officer

Business Wire September 11, 2023

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 25, 2023

DermTech Reports Second-Quarter 2023 Financial Results

Business Wire August 3, 2023

DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire July 19, 2023

DermTech Announces Release Date for Second-Quarter 2023 Financial Results

Business Wire July 17, 2023

DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire July 12, 2023

ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)

Business Wire June 14, 2023

DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire June 7, 2023

DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire June 2, 2023

DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)

Business Wire May 31, 2023

DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire May 11, 2023

DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

Business Wire May 10, 2023

DermTech Appoints Bret Christensen as New President and CEO

Business Wire May 9, 2023

DermTech Reports First-Quarter 2023 Financial Results

Business Wire May 4, 2023

New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months

Business Wire May 1, 2023

DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire April 26, 2023

DermTech Announces Release Date for First-quarter 2023 Financial Results

Business Wire April 13, 2023

DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Business Wire April 11, 2023

New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer

Business Wire April 5, 2023